Date Annoucement
22/11/2019 Change of Directors Interest Notice – Dennis Eck
22/11/2019 Change of Directors Interest Notice – Maria Halasz
22/11/2019 Notice of change of interests of substantial holder
20/11/2019 Results of 2019 Annual General Meeting
19/11/2019 Cellmid Annual General Meeting 2019
12/11/2019 Appendix 3Y – Change of Director’s Interest Notice – Dr Martin Cross
12/11/2019 Appendix 3Y – Change of Director’s Interest Notice – Mr Bruce Gordon
12/11/2019 Appendix 3Y – Change of Director’s Interest Notice – Mr David King
08/11/2019 New issue announcement, application for quotation of additional securities and agreement
06/11/2019 Cellmid Share purchase plan completed
06/11/2019 Cellmid signs trading agreement with API-Priceline
31/10/2019 Cellmid appoints CEO to Advangen USA to expand distribution
24/10/2019 Supplementary Information on Annual general meeting resolutions
23/10/2019 Cellmid notes to the Appendix 4C
16/10/2019 Appendix 3B New issue announcement, application for quotation of additional securities and agreement
16/10/2019 Cellmid Limited Notice of 2019 Annual General Meeting
15/10/2019 Cleansing notice under ASIC corporations (Share and interest purchase plans) instrument 2019- 547
15/10/2019 Share Purchase Plan Offer Booklet
14/10/2019 Cellmid share placement raises $1.5 million
14/10/2019 Cellmid signs new TV shopping agreement for Evolis
10/10/2019 Market Announcement – Cellmid Limited ASX-CDY – Trading Halt
01/10/2019 Cellmid signs new distribution agreement for Evolis and Opens in Europe with leading retailer
27/09/2019 Cellmid receives $840K R&D Tax Credit
16/09/2019 2019 Annual Report to shareholders
16/09/2019 Appendix 4G and Corporate Governance Statement
28/08/2019 Appendix 4E and FY19 Financial Report
28/08/2019 FY19 Results Presentation
28/08/2019 FY2019 Financial Results
22/08/2019 Patent for Improved Midkine Antibody Allowed in Europe
06/08/2019 Cellmid signs distribution agreement for Evolis in South Korea
01/08/2019 Appendix 4C Query
31/07/2019 Appendix 3B New issue annoucement, application for quotation of additional securities and agreement
26/07/2019 Cellmid Notes to the Appendix 4C
10/07/2019 Cellmid Investor Newsletter
05/07/2019 ASX Aware Query
04/07/2019 Cellmid sets another sales record in Q4 FY2019
06/06/2019 Change of Director’s Interest Notice
28/05/2019 Cellmid appoints Lyramid CEO to Accelerate Partnering
28/05/2019 FY2020 Growth Strategy Update May 2019
23/05/2019 Minimum holding buy-back completed
21/05/2019 Minimum holding buy-back closed
30/04/2019 Cellmid’s evolis registered in European Union
29/04/2019 Cellmid notes to the Appendix 4C
18/04/2019 Repayment of Cellmid loan issued to Director pursuant to employee incentive plan
02/04/2019 Cellmid Alopecia Patent allowed in Europe
26/03/2019 Cellmid Investor Newsletter March 2019
19/03/2019 Minimum Holding Share Buy-Back
21/02/2019 Appendix 4D, Half Year Accounts and Strategy Update
07/02/2019 Significant New Findings Published On MIDKINE
23/01/2019 Appendix 4C and Notes to Appendix 4C

 

 

Shop évolis®